Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-06-25
2009-10-20
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S533000, C514S534000, C514S561000, C514S518000, C544S297000, C560S001000, C562S561000
Reexamination Certificate
active
07605166
ABSTRACT:
This application relates to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to alpha-4 integrin or an immunologically active antigen binding fragment in therapeutically effective amounts. The application also relates generally to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and small molecule alpha-4 integrin antagonist that inhibits the alpha-4 integrin (α4 integrin) interaction with VCAM-1. The invention further relates to methods of preparing the compounds and methods of using the compounds and compositions.
REFERENCES:
patent: 6270766 (2001-08-01), Feldman et al.
patent: 6489300 (2002-12-01), Thorsett et al.
patent: 6953802 (2005-10-01), Konradi et al.
patent: 7008949 (2006-03-01), Konradi et al.
patent: 7135477 (2006-11-01), Konradi et al.
patent: 2002/0198172 (2002-12-01), Sandage, Jr. et al.
patent: 2004/0142954 (2004-07-01), Konradi et al.
patent: 1080503 (1967-08-01), None
patent: 97/18838 (1997-05-01), None
patent: WO00/43372 (2000-07-01), None
patent: WO 03/072040 (2003-09-01), None
Kraan et al., “Modulation of Inflammation and Metalloproteinase Expression in Synovial Tissue by Leflunomide and Methotrexate in Patients with Active Rheumatoid Arthritis” Arthritis and Rheumatism (2000) vol. 43, No. 8, pp. 1820-1830.
The Merck Manual of Diagnosis and Therapy, seventeenth edition, published 199 by Merck Research Laboratories, ed. by Beers and Berkow, p. 419.
Barbadillo et al., “Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-α4 antibody in adjuvant arthritis,”Springer Semin Immunopathol., 1995, pp. 427-436, vol. 16, No. 4, Springer-Verlag.
Barbadillo et al., “Anti-VLA4 mAb prevents adjuvant arthritis in Lewis rats,”Arthr. Rheuma., 1993, vol. 36, No. 95.
Issekutz et al., “Monocyte Migration to Arthritis in the Rat Utilizes both CD11/CD18 and Very Late Activation Antigen 4 Integrin Mechanisms,”J. Exp. Med., Mar. 1995, pp. 1197-1203, vol. 181, No. 3, The Rockefeller University Press.
Seiffge, “Protective Effects of Monoclonal Antibody to VLA-4 on Leukocyte Adhesion and Course of Disease in Adjuvant Arthritis in Rats,”The Journal of Rheumatology, 1996, pp. 2086-2091, vol. 23, No. 12.
Zeidler et al., “Therapeutic Effects of Antibodies Against Adhesion Molecules in Murine Collagen Type II-Induced Arthritis,”Autoimmunity, 1995, pp. 245-252, VI. 21, No. 4, Amsterdam B.V., The Netherlands.
FDA Alert for Healthcare Professionals, “Natalizumab (marketed as Tysabri),” Apr. 8, 2005.
International Search Report dated Oct. 3, 2005 (1 pp.).
Sobera L A, et al., “Natalizumab. Treatment of IBD, treatment of multiple sclerosis: AN 100226, AntegrenTM” Drugs of the Future, Barcelona, ES, vol. 25, No. 9, Sep. 9, 2000, pp. 917-921.
Tilley J W: “VLA-4 Antagonists” Expert Opinion on Therapeutic Patents, Ashley Publications, GB, vol. 12, No. 7, 2002, pp. 991-1008.
Maini R, et al., “Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving comcomitant methotrexate: a tamdomised phase III trial” Lancet the, Lancet Limited. London, GB, vol. 354, No. 9194, Dec. 4, 1999, pp. 1932-1939.
Freedman Stephen B.
Konradi Andrei W.
Lieberburg Ivan
Messersmith Elizabeth
Pleiss Michael A.
Crowell & Moring LLP
Elan Pharmaceuticals Inc.
Jiang Shaojia Anna
Olson Eric S
LandOfFree
Methods and compositions for treating rheumatoid arthritis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating rheumatoid arthritis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating rheumatoid arthritis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4102556